Yasushi Shintani

Prof. Yasushi Shintani

Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2020 in Science Immunology
Verified
Journal Article
Open access
PDF file
ESEri Sugiyama
Eri Sugiyama
YTYosuke Togashi
Yosuke Togashi
YTYoshiko Takeuchi
Yoshiko Takeuchi
SSSayoko Shinya
Sayoko Shinya
YTYasuko Tada
Yasuko Tada
HNHiroyoshi Nishikawa
Hiroyoshi Nishikawa
The clinical efficacy of anti–PD-1 (programmed cell death–1) monoclonal antibody (mAb) against cancers with oncogenic driver gene mutations, which often harbor a low tumor mutation burden, is variable, suggesting different contributions of each driver mutation to immune responses. Here, we investigated the immunological phenotypes in the tumor microenvironment (TME) of epidermal growth factor receptor (EGFR)–mutated lung adenocarcinomas, for which anti–PD-1 mAb is largely ineffective. Whereas EGFR-mutated lung adenocarcinomas had a noninflamed TME, CD4+ effector regulatory T cells, which are generally present in the inflamed TME, showed high infiltration. The EGFR signal activated cJun/cJun N-terminal kinase and reduced interferon regulatory factor–1; the former increased CCL22, which recruits CD4+ regulatory T cells, and the latter decreased CXCL10 and CCL5, which induce CD8+ T cell infiltration. The EGFR inhibitor erlotinib decreased CD4+ effector regulatory T cells infiltration in the TME and in combination with anti–PD-1 mAb showed better antitumor effects than either treatment alone. Our results suggest that EGFR inhibitors when used in conjunction with anti–PD-1 mAb could increase the efficacy of immunotherapy in lung adenocarcinomas.

1 September 2016 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
Yasushi ShintaniYasushi Shintani
Yasushi Shintani
AFAyako Fujiwara
Ayako Fujiwara
TKToru Kimura
Toru Kimura
TKTomohiro Kawamura
Tomohiro Kawamura
SFSoichiro Funaki
Soichiro Funaki
MOMeinoshin Okumura
Meinoshin Okumura

20 June 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
HKHirokazu Kimura
Hirokazu Kimura
KFKatsumi Fumoto
Katsumi Fumoto
KSKensaku SHOJIMA
Kensaku SHOJIMA
SNSatoshi Nojima
Satoshi Nojima
YOYoshihito Osugi
Yoshihito Osugi
AKAkira Kikuchi
Akira Kikuchi
Dickkopf1 (DKK1) is a secretory protein that antagonizes oncogenic Wnt signaling by binding to the Wnt coreceptor low-density lipoprotein receptor–related protein 6 (LRP6). DKK1 may also regulate its own signaling to promote cancer cell proliferation, but the mechanism is not understood. Here, we identified cytoskeleton-associated protein 4 (CKAP4) as a DKK1 receptor and evaluated CKAP4-mediated DKK1 signaling in cancer cell proliferation. We determined that DKK1 binds CKAP4 and LRP6 with similar affinity but interacts with these 2 receptors with different cysteine-rich domains. DKK1 induced internalization of CKAP4 in a clathrin-dependent manner, further supporting CKAP4 as a receptor for DKK1. DKK1/CKAP4 signaling activated AKT by forming a complex between the proline-rich domain of CKAP4 and the Src homology 3 domain of PI3K, resulting in proliferation of normal cells and cancer cells. Expression of DKK1 and CKAP4 was frequent in tumor lesions of human pancreatic and lung cancers, and simultaneous expression of both proteins in patient tumors was negatively correlated with prognosis and relapse-free survival. An anti-CKAP4 antibody blocked the binding of DKK1 to CKAP4, suppressed AKT activity in a human cancer cell line, and attenuated xenograft tumor formation in immunodeficient mice. Together, our results suggest that CKAP4 is a potential therapeutic target for cancers that express both DKK1 and CKAP4.

1 November 2011 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
Yasushi ShintaniYasushi Shintani
Yasushi Shintani
AOAkira Okimura
Akira Okimura
KSKatsutoshi Sato
Katsutoshi Sato
TNTomoyuki Nakagiri
Tomoyuki Nakagiri
YKYoshihisa Kadota
Yoshihisa Kadota
MOMeinoshin Okumura
Meinoshin Okumura

26 November 2021 in Science Immunology
Verified
Journal Article
Closed access
YTYoshiko Takeuchi
Yoshiko Takeuchi
TTTokiyoshi Tanegashima
Tokiyoshi Tanegashima
ESEiichi Sato
Eiichi Sato
TITakuma Irie
Takuma Irie
ASAtsuo Sai
Atsuo Sai
HNHiroyoshi Nishikawa
Hiroyoshi Nishikawa
Activation of the WNT pathway allows highly immunogenic cancer cells to escape antitumor immunity and induce cancer progression.

22 July 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
YYYoshiaki Yasumizu
Yoshiaki Yasumizu
NONaganari Ohkura
Naganari Ohkura
HMHisashi Murata
Hisashi Murata
MKMakoto Kinoshita
Makoto Kinoshita
SFSoichiro Funaki
Soichiro Funaki
HMHideki Mochizuki
Hideki Mochizuki
Myasthenia gravis (MG) is a neurological disease caused by autoantibodies against neuromuscular-associated proteins. While MG frequently develops in thymoma patients, the etiologic factors for MG are not well understood. Here, by constructing a comprehensive atlas of thymoma using bulk and single-cell RNA-sequencing, we identify ectopic expression of neuromuscular molecules in MG-type thymoma. These molecules are found within a distinct subpopulation of medullary thymic epithelial cells (mTECs), which we name neuromuscular mTECs (nmTECs). MG-thymoma also exhibits microenvironments dedicated to autoantibody production, including ectopic germinal center formation, T follicular helper cell accumulation, and type 2 conventional dendritic cell migration. Cell–cell interaction analysis also predicts the interaction between nmTECs and T/B cells viaCXCL12-CXCR4. The enrichment of nmTECs presenting neuromuscular molecules within MG-thymoma is further confirmed immunohistochemically and by cellular composition estimation from the MG-thymoma transcriptome. Altogether, this study suggests that nmTECs have a significant function in MG pathogenesis via ectopic expression of neuromuscular molecules.